One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

By Heikki Joensuu, M. Eriksson, K. Sundby Hall, J. Hartmann, D. Pink, J. Schütte, G. Ramadori, P. Hohenberger, J. Duyster, S. Al-Batran and 13 more. Journal of the American Medical Association (JAMA), 2012

997 citations recorded by the source corpus.

Subfields: Gastroenterology, Surgery

View Paper: https://www.semanticscholar.org/paper/525b0c09e05f3c046d47711329bf202366e4d317

Citations in the corpus

• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “65) A [133]”